Evidence map›Paper›PMID 34818122›Full record

ArticlePharmaceutical biology2021

Pharmacokinetic study on the interaction between succinic acid and irbesartan in rats and its potential mechanism.

Yongpeng Wang, Ruping Rui, Xiaoyan Zhang, Bin Sun

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutical biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Yongpeng WangDepartment of Cardiovascular Medicine, Yidu Central Hospital of Weifang, Weifang, Shandong, China.
Ruping RuiDepartment of Cardiovascular Medicine, Yidu Central Hospital of Weifang, Weifang, Shandong, China.
Xiaoyan ZhangQingzhou Tanfang Town Central Health Center, Weifang, Shandong, China.
Bin SunDepartment of Emergency, Yidu Central Hospital of Weifang, Weifang, Shandong, China.
Yidu Central Hospital of Weifang · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

contextSuccinic acid and irbesartan are commonly used drugs in cardiovascular disease treatment. The interaction might occur during their co-administration, which was still unclear.

objectiveTo reveal the effect of succinic acid on the metabolism of irbesartan and its potential mechanism. MATERIALS AND

methodsThe Sprague-Dawley rats (

resultsSuccinic acid increased the AUC (5328.71 ± 959.31 μg/L × h vs. 3340.23 ± 737.75 μg/L × h) and prolonged the half-life of irbesartan (from 12.79 ± 0.73 h to 20.59 ± 6.35 h). The DISCUSSION AND

conclusionsSuccinic acid increased the system exposure of irbesartan via inhibiting CYP2C9. The experiment design of this study also provides a reference for the further validation of this interaction in humans.

Indexed as

Angiotensin II Type 1 Receptor BlockersAnimalsArea Under CurveCytochrome P-450 CYP2C9 InhibitorsCytochrome P-450 Enzyme SystemDrug InteractionsHalf-LifeInhibitory Concentration 50IrbesartanMaleMicrosomes, LiverRatsRats, Sprague-DawleySuccinic AcidAngiotensin II Type 1 Receptor BlockersCYP2C9 protein, ratCytochrome P-450 CYP2C9 InhibitorsCytochrome P-450 Enzyme SystemIrbesartanSuccinic AcidamberCardiovascular diseaseCYP2C9drug–drug interaction

Identifiers

PMID34818122
PMCPMC8635542
OpenAlexW3216906991

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.